Tony Berberabe, MPH

May 28, 2022

Investigators reported that mitomycin gel was not associated with decrements in urinary symptoms, bloating and flatulence, or malaise, and that sexual function only mildly worsened.

April 23, 2022

The CD40 agonist sotigalimab in combination with pembrolizumab yielded promising outcomes in patients with unresectable stage III or IV metastatic melanoma.

September 10, 2021

While survival rates in T-cell acute lymphoblastic leukemia remain around 90%, researchers are optimistic that the use of targeted therapies and immunotherapies will continue to improve treatment options.

July 05, 2021

Treating patients with relapsed/refractory multiple myeloma with Talquetamab at RP2D elicits high clinical response rate.

May 31, 2020

Pediatric precision oncology in a real-world, multinational setting is feasible. For the subgroup of children with very high priority level targets, the INFORM registry provided therapeutic opportunities and new diagnostic information.

September 27, 2016

For men with positive needle biopsy for prostate cancer, active surveillance (AS) did not negatively impact their quality-of-life compared with men who had a negative prostate needle biopsy.

May 19, 2015

Although use of robotic surgery for prostate cancer has surpassed open surgical procedures, the impact of this approach on patient quality of life has not been well-studied.

May 18, 2015

When the United States Preventive Services Task Force (USPSTF) recommended against routine PSA screening for early detection of prostate cancer in May 2012, it caused a sea change in practice patterns among primary care physicians.

April 02, 2015

A new study has found that older, single white males with advanced bladder cancer have the highest suicide risk among those with other cancers of the male genitals and urinary system.

March 18, 2015

The continuing contentious debate about screening for prostate cancer remains top of mind among the public and lay press, but, Leonard G. Gomella, MD, told attendees at the 8th International Prostate Cancer Congress, the decision to screen or not to screen boiled down to "using common sense, shared decision making, and choosing the right patients to screen."